Hartford Longevity Economy ETF (ARCA: HLGE)

Hartford Longevity Economy ETF (ARCA:HLGE), Trade Ideas

Hartford Longevity Economy ETF

High-rolling investors have positioned themselves bullish on IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in IBM often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 12 options trades for IBM. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $38,160, and 11 calls, totaling $646,031.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $185.0 for IBM over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IBM's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IBM's significant trades, within a strike price range of $110.0 to $185.0, over the past month.
<h3>IBM Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715188539_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$19.65</td>
<td>$19.4</td>
<td>$19.5</td>
<td>$150.00</td>
<td>$97.5K</td>
<td>1.8K</td>
<td style="text-align: right;">262</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$19.7</td>
<td>$19.4</td>
<td>$19.5</td>
<td>$150.00</td>
<td>$97.5K</td>
<td>1.8K</td>
<td style="text-align: right;">162</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$19.7</td>
<td>$19.4</td>
<td>$19.5</td>
<td>$150.00</td>
<td>$97.5K</td>
<td>1.8K</td>
<td style="text-align: right;">112</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$19.75</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$150.00</td>
<td>$97.5K</td>
<td>1.8K</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$19.65</td>
<td>$19.45</td>
<td>$19.5</td>
<td>$150.00</td>
<td>$56.5K</td>
<td>1.8K</td>
<td style="text-align: right;">291</td>
</tr>
</tbody>
</table>

<h3>About IBM</h3>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients—which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.
In light of the recent options history for IBM, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of IBM</h3>
<ul>
<li>Trading volume stands at 1,428,017, with IBM's price up by 0.46%, positioned at $169.15.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
<h3>Professional Analyst Ratings for IBM</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $169.8.
<ul>
<li>An analyst from UBS has decided to maintain their Sell rating on IBM, which currently sits at a price target of $130. </li>
<li>In a cautious move, an analyst from Exane BNP Paribas downgraded its rating to Underperform, setting a price target of $145. </li>
<li>Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for IBM, targeting a price of $210. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on IBM with a target price of $185. </li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on IBM with a target price of $179. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IBM options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

IBM Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WYNN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Wynn Resorts.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 46%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $104,838, and 11 are calls, for a total amount of $606,215.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $105.0 for Wynn Resorts over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Wynn Resorts's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Wynn Resorts's whale trades within a strike price range from $75.0 to $105.0 in the last 30 days. 
<h3>Wynn Resorts Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715188533_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$95.00</td>
<td>$93.7K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">810</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$4.95</td>
<td>$97.50</td>
<td>$74.2K</td>
<td style="text-align: right;">841</td>
<td style="text-align: right;">503</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$2.92</td>
<td>$2.9</td>
<td>$2.9</td>
<td>$100.00</td>
<td>$72.7K</td>
<td style="text-align: right;">518</td>
<td style="text-align: right;">353</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.5</td>
<td>$5.85</td>
<td>$6.35</td>
<td>$105.00</td>
<td>$63.5K</td>
<td style="text-align: right;">27</td>
<td style="text-align: right;">102</td>
</tr>
<tr>
<td>WYNN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$25.8</td>
<td>$25.3</td>
<td>$25.8</td>
<td>$75.00</td>
<td>$51.6K</td>
<td style="text-align: right;">824</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Wynn Resorts</h3>
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to open a new building next to its existing Wynn Palace resort in around 2028. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively.
Following our analysis of the options activities associated with Wynn Resorts, we pivot to a closer look at the company's own performance.
<h3>Current Position of Wynn Resorts</h3>
<ul>
<li>With a volume of 2,577,970, the price of WYNN is down -2.53% at $94.77. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 91 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wynn Resorts options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

WYNN

This Is What Whales Are Betting On Wynn Resorts

WIIM

IPAR

Inter Parfums shares are trading lower after the company reported worse-than-expected Q1 financial results and reaffirmed soft FY24 guidance.

Barrington Research analyst Alexander Paris maintains Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) with a Outperform and raises the price target from $160 to $165.

News

Price Target

Analyst Ratings

LOPE

Barrington Research Maintains Outperform on Grand Canyon Education, Raises Price Target to $165

TD Cowen analyst Gautam Khanna maintains TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) with a Buy and raises the price target from $1300 to $1400.

TD Cowen Maintains Buy on TransDigm Gr, Raises Price Target to $1400

Icahn Enterprises L.P. shares are trading higher after the company reported Q1 financial results.

VECO

Veeco shares are trading higher after the company reported better-than-expected Q1 financial results.

TD Cowen analyst Bryan Bergin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Hold and raises the price target from $70 to $75.

TD Cowen Maintains Hold on Fidelity National Info, Raises Price Target to $75

CERT

Certara shares are trading lower after the company reported Q1 financial results.

<a href="https://www.beyondmeat.com/en-US/whats-new/mc-donald-s-deutschland-weltstars-bill-und-tom-kaulitz-bekommen-eigenes-mc-plant-menue-mit-mc-plant-burger-und-mc-plant-nuggets" title="https://www.beyondmeat.com/en-US/whats-new/mc-donald-s-deutschland-weltstars-bill-und-tom-kaulitz-bekommen-eigenes-mc-plant-menue-mit-mc-plant-burger-und-mc-plant-nuggets">https://www.beyondmeat.com/en-US/whats-new/mc-donald-s-deutschland-weltstars-bill-und-tom-kaulitz-bekommen-eigenes-mc-plant-menue-mit-mc-plant-burger-und-mc-plant-nuggets</a>

BYND

UPDATE: Beyond Meat Re-Issues Release 'MCDONALD'S GERMANY LAUNCHES MCPLANT® FAMOUS MEALS'

POWI

Power Integrations shares are trading higher after the company reported better-than-expected Q1 financial results.

TD Cowen analyst Matthew Ramsay maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Buy and raises the price target from $100 to $115.

CRUS

TD Cowen Maintains Buy on Cirrus Logic, Raises Price Target to $115

WK Kellogg shares are trading lower after Exane BNP Paribas downgraded the stock from Neutral to Underperform and announced a $20 price target.

A young patient&nbsp;<a target="_blank" href="https://www.parentprojectmd.org/wp-content/uploads/2024/05/Pfizer-DMD-PAG-Letter_Final.pdf" rel="noreferrer noopener">died</a>&nbsp;due to cardiac arrest after receiving&nbsp;Pfizer Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy.
The boy was enrolled in Phase 2 DAYLIGHT study&nbsp;studying&nbsp;the treatment in boys at least two years old and under four years old.&nbsp;
The patient received the&nbsp;investigational gene therapy,&nbsp;fordadistrogene&nbsp;movaparvovec&nbsp;(PF-06939926), in early 2023.
Citing Pfizer, Reuters highlighted that the boy died of cardiac arrest but that&nbsp;it was still working to understand what happened and the exact cause.
All participants will be followed in the&nbsp;<a target="_blank" href="https://www.clinicaltrials.gov/study/NCT05429372" rel="noreferrer noopener">study</a>&nbsp;for five years after treatment with gene therapy, initiated in August 2022 and estimated to be completed in early 2029,&nbsp;as per the data from Clinicaltrial.gov.
Pfizer and the independent external data monitoring committee said&nbsp;that the&nbsp;data is&nbsp;being reviewed&nbsp;to understand the potential cause.
The gene therapy candidate is also&nbsp;being tested&nbsp;in another late-stage DMD&nbsp;<a target="_blank" href="https://clinicaltrials.gov/study/NCT04281485" rel="noreferrer noopener">study</a>, CIFFREO Phase 3, in patients in boys at least&nbsp;4&nbsp;years old and less than eight years old.
There is not an impact&nbsp;to&nbsp;our expectation of having late-stage results, the company told Reuters in its email.
&#8220;We anticipate&nbsp;potentially beginning the primary analysis of the Phase 3 CIFFREO trial of&nbsp;fordadistrogene&nbsp;movaparvovec&nbsp;at the end of this month and sharing top-line results relatively soon,&#8221; it added.
Pfizer has decided to pause dosing associated with the cross-over portion&nbsp;of the&nbsp;CIFFREO study.&nbsp;
Beyond CIFFREO, the dosing pause does not apply to other ongoing trials in the&nbsp;fordadistrogene&nbsp;movaparvovec&nbsp;program&nbsp;as&nbsp;dosing has&nbsp;been completed&nbsp;in those studies.
It is the second death to be associated with&nbsp;fordadistrogene&nbsp;movaparvovec&nbsp;during a clinical study.
In December 2021, Pfizer paused screening and dosing in a Phase 1b trial assessing&nbsp;fordadistrogene&nbsp;movaparvovec&nbsp;after the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24723532/pfizers-duchenne-gene-therapy-trial-put-on-fda-hold-after-patient-death" rel="noreferrer noopener">death of a young man</a>.
The FDA&nbsp;lifted the clinical hold&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/22/04/26875641/fda-gives-green-signal-to-pfizers-duchenne-gene-therapy-trial" rel="noreferrer noopener">in April 2022</a>.
Price Action: PFE shares are up 1.31% at $28.14 at last check Wednesday.
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial

TD Cowen analyst John Blackledge maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Hold and raises the price target from $14 to $16.

LYFT

TD Cowen Maintains Hold on Lyft, Raises Price Target to $16

Earnings

Earnings Beats

JOBY

Joby Aviation Q1 2024 GAAP EPS $(0.14) Beats $(0.18) Estimate, Sales $25.00K

TD Cowen analyst Krish Sankar maintains Ichor Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) with a Buy and raises the price target from $42 to $48.

ICHR

TD Cowen Maintains Buy on Ichor Hldgs, Raises Price Target to $48

Mastercard Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) is collaborating with&nbsp;major&nbsp;U.S. banks to test a shared-ledger technology&nbsp;that will&nbsp;enable the unified settlement of tokenized assets, including commercial bank money and Treasury and investment-grade debt securities.&nbsp;
This Regulated Settlement Network proof-of-concept will simulate dollar transactions, aiming to simplify and speed up international and system-wide transactions while reducing errors and fraud risks, Bloomberg&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-05-08/mastercard-citi-jpmorgan-test-ledger-for-settling-bank-money?srnd=technology-vp&amp;sref=TBDibEcD" rel="noreferrer noopener">cites</a>&nbsp;a Mastercard statement.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38641032/jack-ma-backed-ant-groups-alipay-broadens-payment-reach-across-continents-how-its-shaping-global-com" rel="noreferrer noopener">Jack Ma Backed Ant Group&#8217;s Alipay+ Broadens Payment Reach Across Continents: How It&#8217;s Shaping Global Commerce?</a>
The new ledger technology can revolutionize financial operations by allowing commercial bank money, wholesale central bank money, and securities like investment-grade debt to reside on a single system once they&nbsp;are tokenized.&nbsp;
The initiative builds on a 12-week pilot that started in late 2022, focusing on domestic interbank and cross-border dollar transactions.
Major financial institutions participating in this trial include&nbsp;Citigroup Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>),&nbsp;JPMorgan Chase &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), US Bancorp,&nbsp;Wells Fargo &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), and&nbsp;Visa Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), along with Swift, TD Bank NA, and Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>).&nbsp;
Experts from the&nbsp;Bank of New York Mellon Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) and the International Swaps and Derivatives Association contribute to the project. Earlier in May, Mastercard reported&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38555665/mastercard-says-consumer-spending-is-healthy-clocks-10-revenue-growth-in-q1" rel="noreferrer noopener">fiscal first-quarter</a>&nbsp;net revenues of $6.35 billion, up 10%&nbsp;year over year,&nbsp;beating the analyst consensus estimate of&nbsp;$6.34 billion. Adjusted EPS of $3.31 beat the&nbsp;analyst consensus estimate of $3.24.
Michael Miebach, CEO of&nbsp;Mastercard&nbsp;said,&nbsp;&#8220;We are driving growth in electronic payments by scaling innovative technologies like tokenization.&#8221;
Mastercard stock gained 18% in the last 12 months. Investors can gain exposure to the stock via&nbsp;IShares U.S. Financial Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;Fidelity MSCI Financials Index ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNCL#NYSE">FNCL</a>).
Price Action: MA shares are trading lower by 0.04% at $452.87 at the last check Wednesday.
Photo via Shutterstock

Tech

Media

FNCL

iShares Trust Dow Jones US Financial Services Index Fund

ZION

Mastercard's New Tech Could Change How Banks Handle Money and Securities

Canaccord Genuity analyst David Hynes maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Buy and lowers the price target from $22 to $20.

Canaccord Genuity Maintains Buy on ZoomInfo Technologies, Lowers Price Target to $20

TD Cowen analyst Derrick Wood maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Buy and raises the price target from $34 to $37.